



Maye AF/1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Examining Operations

Applicant(s): Mosca, et al.

Serial No: 09/267,456

Art Unit: 1644

Filed: March 12, 1999

Examiner: Ewoldt

Title: Mesenchymal Stem Cells as Immunosuppressants

Attorney

Docket No.: 640100-295

Customer No. 27162

TRANSMITTAL LETTER

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SIR:

Enclosed please find the following:

1. Amendment; and
2. A self-addressed, postage paid, return receipt postcard, date stamp and return of which is respectfully requested.

The Commissioner is authorized to charge payment of any additional filing fees required under 37 C.F.R. 1.16 associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Raymond J. Lillie 12/12/03
Raymond J. Lillie, Esq. Date

#204236 v1

Respectfully submitted,

Raymond J. Lillie
Raymond J. Lillie, Esq.
Reg. No. 31,778

CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, New Jersey 07068
T: (973) 994-1700
F: (973) 994-1744



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Mosca, et al.
Serial No.: 09/267,456
Filed: March 12, 1999
For: Mesenchymal Stem Cells as Immunosuppressants
Group: 1644
Examiner: Ewoldt

Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR 1.116

SIR:

This is an Amendment in response to the Final Rejection dated October 17, 2003.

A. Introductory Comments:

Claims 37 and 44 are being amended. Claims 53-59 are being cancelled without prejudice.